City Therapeutics, Inc. CTY
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -7.54%
- 1 year
- -7.54%
- Open
- 22.08
- Prev close
- 22.14
- Mkt cap
- 1.04B
- Vol
- 116.79K
- Avg vol
- 391.29K
- EPS
- -2.53
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 20.37
- High
- 22.26
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Inst. own
- 37.64%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 21.21
- 200-d avg
- 21.21
- 1y target
- 0.00
News
1 week ago barrons.com
Forget Anthropic: Biotech Is Quietly Dominating the IPO Sphere
As investors wait for the Claude developer to file its official IPO paperwork, several biotechs are going public and doing just fine.
1 week ago globenewswire.com
City Therapeutics Announces Closing of $230.0 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
City Therapeutics Announces Closing of $230.0 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Addition
2 weeks ago seekingalpha.com
U.S. IPO Weekly Recap: Biotechs City Therapeutics And Iambic Headline The Week's Pricings
Three IPOs and two SPACs priced this week, and two SPACs submitted filings. No IPOs are currently scheduled for the week ahead as the year's next mega IPO potentially comes into view. Street research…
2 weeks ago globenewswire.com
City Therapeutics Announces Pricing of Upsized Initial Public Offering
CAMBRIDGE, Mass., Oct. 15, 2026 (GLOBE NEWSWIRE) -- City Therapeutics, Inc. (Nasdaq: CTY) (“City” or “City Therapeutics”), a clinical-stage biotechnology company developing the next generation of RNA…
3 weeks ago reuters.com
City Therapeutics eyes valuation of up to $956.3 million in US IPO amid biotech listing push
City Therapeutics on Friday said it is targeting a valuation of up to $956.3 million in its US initial public offering, as biotech companies press ahead with listings despite market uncertainty.
1 month ago seekingalpha.com
City Therapeutics, RNAi Treatment Developer, Files For IPO
City Therapeutics is advancing next-generation RNAi therapeutics, with its lead program CITY-FXI targeting thrombosis and showing promising early Phase 1 trial results. CTY boasts significant big…
6 years ago seekingalpha.com
Baby Bonds Complete Review
A review of all baby bonds. All the baby bonds sorted in categories.